Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Controlled Study of REACT in Participants With Type 2 Diabetes and Chronic Kidney Disease (REGEN-016)

NCT05286853 is registered in ClinicalTrials.gov with Prokidney as lead sponsor.

NCT NCT05286853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05286853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Controlled Study of REACT in Participants With Type 2 Diabetes and Chronic Kidney Disease (REGEN-016)
Lead sponsor
Prokidney
Phase
Phase 3
Overall status
Withdrawn
Start date
July 17, 2024
Completion date
September 3, 2024
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, type 2 diabetes mellitus